DDC treatment resulted in a dose-dependent increase in intracellular O2.− in VEN-S MOLM14 and OCI-AML2 AML cells and three other hematopoietic cell lines, RPMI8226 myeloma, Jurkat T-ALL, and OCI-Ly3 DLBCL (Figs. 2A and S3A). This evidence concerns the gene CD8B and plasma cell myeloma.